Süleyman Serdar Koca1, Murat Kara2, Metin Özgen3, Ramazan Dayanan4, Caner Feyzi Demir5, Kader Aksoy6, Nevin İlhan7, Emir Dönder4, Ahmet Işık1. 1. Department of Rheumatology, Fırat University School of Medicine, Elazığ, Turkey. 2. Department of Medical Genetics, Sıtkı Koçman University School of Medicine, Muğla, Turkey. 3. Department of Rheumatology, 19 Mayıs University School of Medicine, Samsun, Turkey. 4. Department of Internal Medicine, Fırat University School of Medicine, Elazığ, Turkey. 5. Department of Neurology, Fırat University School of Medicine, Elazığ, Turkey. 6. Department of Endocrinology, Fırat University School of Medicine, Elazığ, Turkey. 7. Department of Biochemistry, Fırat University School of Medicine, Elazığ, Turkey.
Abstract
OBJECTIVE: Chronic inflammatory diseases are associated with altered body composition. Ghrelin has anti-inflammatory effects, and its level is altered in obesity and inflammatory diseases. The aim of the study was to evaluate the prevalence of obesity and ghrelin and obestatin levels in patients with Behçet's disease (BD). MATERIAL AND METHODS: One hundred and forty-three (143) patients with BD and 112 healthy controls (HC) were enrolled. Participants were subdivided according to the body mass index (BMI) as lean (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2). In addition to the routine evaluations (fasting blood glucose, lipid profile, and kidney and liver function tests), serum acylated-ghrelin (AG), unacylated-ghrelin (UAG), total ghrelin (TG) and obestatin levels were analyzed. Student's t-test and chi-square test were used for statistical analysis. RESULTS: The prevalence of obesity was relatively lower in the BD group than in the HC group (12.6% vs. 20.5%, p=0.089). Serum ghrelin levels were similar in the BD and HC groups (p>0.05 for all) although the obestatin level was higher in the BD group compared to the HC group (p<0.001). Serum UAG, TG and obestatin levels were lower in obese BD patients (n=18) than non-obese BD patients (p=0.027, p=0.014 and p=0.001, respectively). CONCLUSION: The obestatin level was high and the prevalence of obesity was low in the BD group. Moreover, obese BD patients had low obestatin levels. These results suggest that obestatin may protect BD patients from obesity.
OBJECTIVE: Chronic inflammatory diseases are associated with altered body composition. Ghrelin has anti-inflammatory effects, and its level is altered in obesity and inflammatory diseases. The aim of the study was to evaluate the prevalence of obesity and ghrelin and obestatin levels in patients with Behçet's disease (BD). MATERIAL AND METHODS: One hundred and forty-three (143) patients with BD and 112 healthy controls (HC) were enrolled. Participants were subdivided according to the body mass index (BMI) as lean (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2). In addition to the routine evaluations (fasting blood glucose, lipid profile, and kidney and liver function tests), serum acylated-ghrelin (AG), unacylated-ghrelin (UAG), total ghrelin (TG) and obestatin levels were analyzed. Student's t-test and chi-square test were used for statistical analysis. RESULTS: The prevalence of obesity was relatively lower in the BD group than in the HC group (12.6% vs. 20.5%, p=0.089). Serum ghrelin levels were similar in the BD and HC groups (p>0.05 for all) although the obestatin level was higher in the BD group compared to the HC group (p<0.001). Serum UAG, TG and obestatin levels were lower in obese BDpatients (n=18) than non-obese BDpatients (p=0.027, p=0.014 and p=0.001, respectively). CONCLUSION: The obestatin level was high and the prevalence of obesity was low in the BD group. Moreover, obese BDpatients had low obestatin levels. These results suggest that obestatin may protect BD patients from obesity.
Authors: Antonios Stavropoulos-Kalinoglou; Giorgos S Metsios; Yiannis Koutedakis; Alan M Nevill; Karen M Douglas; Athanasios Jamurtas; Jet J C S Veldhuijzen van Zanten; Mourad Labib; George D Kitas Journal: Ann Rheum Dis Date: 2007-02-08 Impact factor: 19.103
Authors: Artur Dembiński; Zygmunt Warzecha; Piotr Ceranowicz; Jakub Cieszkowski; Marcin Dembiński; Agata Ptak-Belowska; Atsukasu Kuwahara; Ikuo Kato Journal: Med Sci Monit Date: 2011-08